Sign In
Buy MDGL
$513.43
+0.550 (+0.107%)
At Close: Jun 23, 2026
Madrigal Pharmaceuticals Is Still Undervalued After Resmetirom's Phase 3 Success
10:57am, Wednesday, 21'st Dec 2022
Madrigal Pharmaceuticals announced positive top-line results from their phase three trial evaluating Resmetirom as a treatment for NASH fibrosis on Monday, sending shares up by almost 300 percent sinc
Top M&A Target: Madrigal Pharmaceuticals Could Be Next After Successful NASH Data, Analyst Says
08:00pm, Tuesday, 20'th Dec 2022 Benzinga
Madrigal Pharmaceuticals Inc (NASDAQ: MDGL) has announced positive topline results from the pivotal Phase 3 MAESTRO-NASH biopsy trial of resmetirom.
JMP has raised the price target from $182 to $31
Madrigal Pharmaceuticals Gets Price Target Bumps By Analysts Following Successful NASH Study
05:42pm, Tuesday, 20'th Dec 2022 Benzinga
Madrigal Pharmaceuticals Inc (NASDAQ: MDGL) announced positive topline results from the pivotal Phase 3 MAESTRO-NASH biopsy trial of resmetirom.
Madrigal Pharmaceuticals shares jumped 268.1% to close
Madrigal (MDGL) Soars as Resmetirom Meets Goal in NASH Study
04:15pm, Tuesday, 20'th Dec 2022 Zacks Investment Research
Madrigal's (MDGL) phase III MAESTRO-NASH study evaluating resmetirom for treating nonalcoholic steatohepatitis and liver fibrosis meets both primary endpoints. Stock rises.
Analyst Ratings for Madrigal Pharmaceuticals
03:04pm, Tuesday, 20'th Dec 2022 Benzinga
Madrigal Pharmaceuticals (NASDAQ:MDGL) has observed the following analyst ratings within the last quarter:
Bullish
Somewhat Bullish
Indifferent
Somewhat Bearish
Bearish
Total Ratings
1
3
0
0
Tesla To $285? Here Are 10 Other Price Target Changes For Tuesday
01:05pm, Tuesday, 20'th Dec 2022 Benzinga
Wells Fargo raised Ross Stores, Inc. (NASDAQ: ROST) price target from $120 to $135. Wells Fargo analyst Ike Boruchow maintained an Overweight rating on the stock. Ross Stores shares fell 0.9% to cl
Here's How An Options Trader Made $5.5 Million In One Day
01:05pm, Tuesday, 20'th Dec 2022 Benzinga
Madrigal Pharmaceuticals Inc (NASDAQ: MDGL) shares rose sharply on Monday after the company announced positive topline results from the pivotal Phase 3 MAESTRO-NASH (fatty liver disease) biopsy trial
Madrigal (MDGL) Soars as Resmetirom Meets Goal in NASH Study
12:47pm, Tuesday, 20'th Dec 2022
Madrigal's (MDGL) phase III MAESTRO-NASH study evaluating resmetirom for treating nonalcoholic steatohepatitis and liver fibrosis meets both primary endpoints. Stock rises.
Tesla, Amazon, Apple, Madrigal, Walt Disney: Why These 5 Stocks Are Drawing Investors' Attention Today
12:47am, Tuesday, 20'th Dec 2022 Benzinga
Major Wall Street indices closed in the red on Monday as investor optimism on the much-anticipated Santa Claus rally began to fade over fears of recession gaining momentum. The Dow Jones index closed
Why Cosmos Health Shares Are Trading Lower By Around 60%? Here Are 79 Stocks Moving In Monday's Mid-Day Session
06:38pm, Monday, 19'th Dec 2022 Benzinga
Gainers
Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) shares jumped 259% to $229.35 after the company announced resmetirom achieved both primary endpoints in NASH and liver fibrosis trial.
Axcella H
Why Madrigal Pharmaceuticals Stock Is Crushing It Today
04:50pm, Monday, 19'th Dec 2022 The Motley Fool
The company reported stellar late-stage clinical trial results for its experimental NASH (nonalcoholic steatohepatitis) drug.
Madrigal Pharmaceuticals, Cerevel Therapeutics And Some Other Big Stocks Moving Higher On Monday
03:49pm, Monday, 19'th Dec 2022 Benzinga
U.S. stocks traded mixed, with the Nasdaq Composite dropping around 90 points on Monday. Here are some big stocks recording gains in today’s session.
Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL)
Tesla's Bouncing, but This Nasdaq Stock Tripled Monday Morning
03:32pm, Monday, 19'th Dec 2022 The Motley Fool
Good news can come in different forms.
Madrigal's Successful Late-Stage Trial Draws Options Bulls
03:15pm, Monday, 19'th Dec 2022
Madrigal Pharmaceuticals Inc (NASDAQ:MDGL) is surging, last seen up 250.3% to trade at $223.50, after its experimental drug Resmetirom met the main goals of a late-stage study.
Why Madrigal Pharmaceuticals Stock Is Crushing It Today
11:50am, Monday, 19'th Dec 2022
The company reported stellar late-stage clinical trial results for its experimental NASH (nonalcoholic steatohepatitis) drug.
